OlympiA (GBG 82)

Olaparib as adjuvant Treatment in patients with BRCA1/2 mutations and high risk HER2 negative primary breast cancer

  1. Startpage
  2. Trials
  3. OlympiA

Introduction

Olaparib as adjuvant Treatment in patients with BRCA1/2 mutations and high risk HER2 negative primary breast cancer

 

Study codes: BIG 6-13, NSABP B-55

News

Study status: end of recruitment reached

Study was released in CTIS.

Interim results on trials.gov.

Design

Systemic neoadjuvant or adjuvant chemotherapy with 6 cycles of anthracyclines, taxanes or in combination. Platinum pre-treatment is permitted. Participation after completion of local therapy and radiotherapy.

  • Arm A: Olaparib 2X daily (till), 300 mg (2X150mg), 600mg/d
  • Arm B: Placebo 2X daily (till), 300 mg (2X150mg), 600mg/d

Patient profile:

  • Triple Negative
  • Confirmed BRCA-status

Contact

Project management

Anna Huber, Dr. Ioannis Gkantiragas

+4961027480440